HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with ...

A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

Patients with certain subtypes of breast cancer may be at higher risk for death by waiting more than 42 days after their ...

Ananda Lewis chose alternative breast cancer treatments for years before her death this month. Here’s what she tried and what ...

A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

For the first time in Australia, a drug that can delay the growth of tumours is available under the Pharmaceutical Benefits ...